Emergent BioSolutions Inc. revised earnings guidance for the year 2024. For the year, the company expects total revenues of $1,000 million to $1,100 million compared to previous guidance of $900 million to $1,100 million. Net loss of $148 million to $98 million compared to previous guidance of $183 million to $133 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.7 USD | +11.98% | +15.38% | +137.50% |
May. 02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
May. 02 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+137.50% | 267M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024